ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
Executive Summary
Institute for Clinical and Economic Review launching pilot program that allows drug assessment models to be inspected, but not manipulated, by manufacturers.
You may also be interested in...
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.
Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions
Industry-funded Open-Source Value Project aims to disseminate tools to the marketplace for customized value assessments, as opposed to offering a specific estimate of value for pricing and coverage decisions.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.